fibroblast growth factor Search Results


94
Gold Biotechnology Inc fgf2
Fgf2, supplied by Gold Biotechnology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fgf2/product/Gold Biotechnology Inc
Average 94 stars, based on 1 article reviews
fgf2 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

94
MedChemExpress fgf2 recombinant protein
Fgf2 Recombinant Protein, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fgf2 recombinant protein/product/MedChemExpress
Average 94 stars, based on 1 article reviews
fgf2 recombinant protein - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

94
Boster Bio human fgf2 elisa kit
Fig. 4. (A) Detection of ADSCs proliferation by ADM coating at different times. Quantification of (B) EGF and (C) <t>FGF2</t> in ADSCs paracrine products. *** P < 0.001 representing a significant difference as compared with ADM (3 min) and TLWDA.
Human Fgf2 Elisa Kit, supplied by Boster Bio, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human fgf2 elisa kit/product/Boster Bio
Average 94 stars, based on 1 article reviews
human fgf2 elisa kit - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

94
Proteintech buffer
Fig. 4. (A) Detection of ADSCs proliferation by ADM coating at different times. Quantification of (B) EGF and (C) <t>FGF2</t> in ADSCs paracrine products. *** P < 0.001 representing a significant difference as compared with ADM (3 min) and TLWDA.
Buffer, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/buffer/product/Proteintech
Average 94 stars, based on 1 article reviews
buffer - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

93
Cusabio elisa kit
Fig. 4. (A) Detection of ADSCs proliferation by ADM coating at different times. Quantification of (B) EGF and (C) <t>FGF2</t> in ADSCs paracrine products. *** P < 0.001 representing a significant difference as compared with ADM (3 min) and TLWDA.
Elisa Kit, supplied by Cusabio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/elisa kit/product/Cusabio
Average 93 stars, based on 1 article reviews
elisa kit - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

94
MedChemExpress recombinant fgf1
Fig. 4. (A) Detection of ADSCs proliferation by ADM coating at different times. Quantification of (B) EGF and (C) <t>FGF2</t> in ADSCs paracrine products. *** P < 0.001 representing a significant difference as compared with ADM (3 min) and TLWDA.
Recombinant Fgf1, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant fgf1/product/MedChemExpress
Average 94 stars, based on 1 article reviews
recombinant fgf1 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

94
BioVendor Instruments elisa
Fig. 4. (A) Detection of ADSCs proliferation by ADM coating at different times. Quantification of (B) EGF and (C) <t>FGF2</t> in ADSCs paracrine products. *** P < 0.001 representing a significant difference as compared with ADM (3 min) and TLWDA.
Elisa, supplied by BioVendor Instruments, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/elisa/product/BioVendor Instruments
Average 94 stars, based on 1 article reviews
elisa - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

93
Proteintech basic thermostable fibroblast growth factor
Fig. 4. (A) Detection of ADSCs proliferation by ADM coating at different times. Quantification of (B) EGF and (C) <t>FGF2</t> in ADSCs paracrine products. *** P < 0.001 representing a significant difference as compared with ADM (3 min) and TLWDA.
Basic Thermostable Fibroblast Growth Factor, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/basic thermostable fibroblast growth factor/product/Proteintech
Average 93 stars, based on 1 article reviews
basic thermostable fibroblast growth factor - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

92
Cusabio fgf8 protein
a , Schematic summarizing factors and gene markers involved in human cortical area specification. b , Overview of the protocol used to treat neural organoids with patterning factors from 3 to 5 div. Diff, differentiation medium ± vitamin A. c , Percentage of organoids with detectable SP8 > GFP expression after treatment with rostralizing factors (left) or EMX1>mNeonGreen expression after treatment with caudalizing factors (right). CHRDL1, chordin like 1; FST, follistatin; SB, SB-431542 dual SMAD inhibitor; CER1, cerberus 1; CHIR, GSK-3β inhibitor CHIR99021; WNT1, Wnt family member 1. Data indicate the mean ± s.d. from three lines per treatment ( n = 15 organoids per condition and line; except n = 16 for <t>FGF8</t> high and CHIR low; n = 20, n = 19 and n = 17 for Chir high, and n = 18, n = 19 and n = 17 for Wnt1 treatment for the three lines). P values from one-way analysis of variance (ANOVA; Tukey’s multiple-comparisons test) for comparisons to untreated conditions are provided. d , Experimental procedure for assembloid generation with the SP8 > GFP line and OrEBs. D, day after EB formation; Diff, differentiation medium ± vitamin A; ULA, ultra-low attachment plate . e , RT–qPCR analysis of FGF8 target genes expressed in the SP8 > GFP EBs severed from OrEB after 1 day of co-culture. Data are the log of expression over TBP , shown as the mean ± s.d. ( n = 6 EBs for 0%, n = 5 for 1%, n = 5 for 10% grown from three independent clones). P values are the results of one-way ANOVA. f , GFP intensity of the organoids from g . Whiskers are the minima to maxima, boxes represent the 25th to 75th percentiles (Q1 to Q3) and lines indicate the median ( n = 7 organoids for 0%, n = 11 for 1%, n = 19 for 10%, grown from three independent clones). P values are the results of one-way ANOVA. g , Images of organoids generated with the SP8 > GFP transgenic line and co-culture with OrEBs at 60 div (scale bars, 500 µm). **** P < 0.0001, *** P < 0.001, ** P < 0.01, * P < 0.1. a.u., arbitrary units.
Fgf8 Protein, supplied by Cusabio, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fgf8 protein/product/Cusabio
Average 92 stars, based on 1 article reviews
fgf8 protein - by Bioz Stars, 2026-03
92/100 stars
  Buy from Supplier

93
Proteintech human fgf21 analog
Construction, purification, and characterization of <t>FGF21-164.</t> ( A ) FGF21-164 sequence and FGF21 sequence. In the FGF21-164 sequence, red marked the mutated amino acid and blue represents the TR acid sequence from hCD164. In the FGF21 sequence, the red-labeled amino acid represents the amino acid sequence whose n-terminal is deleted in FGF21-164. ( B ) Subcloned cell culture supernatants expressing FGF21-164 and FGF21 were analyzed using Western blotting (Lane M: molecular weight marker. Lane 1~7: FGF21-164 clones 1, 2, 3, A4, B2, F3, and H4. Line 8: FGF21 clone2). ( C ) The purified FGF21-164 and FGF21 were assayed using SDS-PAGE and Western blotting (Lane M: molecular weight marker. Lane 1: purified FGF21-164. Line 2: purified FGF21). ( D ) Purity and hydrodynamic radius of FGF21-164 were analyzed using SEC-HPLC. ( E ) MALDI-TOF mass-spectrometry analysis of FGF21-164. ([M + H] + denotes the singly charged ionic forms, and [M + 2H] 2+ denotes doubly charged ionic forms). ( F ) Circular Dichroism (CD) spectra of FGF21-164 and FGF21.
Human Fgf21 Analog, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human fgf21 analog/product/Proteintech
Average 93 stars, based on 1 article reviews
human fgf21 analog - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

93
Boster Bio fgf21
Construction, purification, and characterization of <t>FGF21-164.</t> ( A ) FGF21-164 sequence and FGF21 sequence. In the FGF21-164 sequence, red marked the mutated amino acid and blue represents the TR acid sequence from hCD164. In the FGF21 sequence, the red-labeled amino acid represents the amino acid sequence whose n-terminal is deleted in FGF21-164. ( B ) Subcloned cell culture supernatants expressing FGF21-164 and FGF21 were analyzed using Western blotting (Lane M: molecular weight marker. Lane 1~7: FGF21-164 clones 1, 2, 3, A4, B2, F3, and H4. Line 8: FGF21 clone2). ( C ) The purified FGF21-164 and FGF21 were assayed using SDS-PAGE and Western blotting (Lane M: molecular weight marker. Lane 1: purified FGF21-164. Line 2: purified FGF21). ( D ) Purity and hydrodynamic radius of FGF21-164 were analyzed using SEC-HPLC. ( E ) MALDI-TOF mass-spectrometry analysis of FGF21-164. ([M + H] + denotes the singly charged ionic forms, and [M + 2H] 2+ denotes doubly charged ionic forms). ( F ) Circular Dichroism (CD) spectra of FGF21-164 and FGF21.
Fgf21, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fgf21/product/Boster Bio
Average 93 stars, based on 1 article reviews
fgf21 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

90
Boster Bio fgfr3
IHC staining of mp53 in SCCHN samples shows mainly nuclear and some cytoplasmic expression patterns. IHC staining of <t>FGFR3</t> shows membrane and cytoplasmic expression. Four representative images are presented: mp53+/FGFR3+, mp53+/FGFR3-, mp53-/FGFR3+, mp53-/FGFR3- and negative control. (200 x magnification).
Fgfr3, supplied by Boster Bio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fgfr3/product/Boster Bio
Average 90 stars, based on 1 article reviews
fgfr3 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Fig. 4. (A) Detection of ADSCs proliferation by ADM coating at different times. Quantification of (B) EGF and (C) FGF2 in ADSCs paracrine products. *** P < 0.001 representing a significant difference as compared with ADM (3 min) and TLWDA.

Journal: Materials & Design

Article Title: Multifunctional nanofiber-based dressings in coordination with adipose-derived stem cells for accelerated burn wound healing

doi: 10.1016/j.matdes.2025.113929

Figure Lengend Snippet: Fig. 4. (A) Detection of ADSCs proliferation by ADM coating at different times. Quantification of (B) EGF and (C) FGF2 in ADSCs paracrine products. *** P < 0.001 representing a significant difference as compared with ADM (3 min) and TLWDA.

Article Snippet: Human EGF enzyme-linked immunosorbent assay (ELISA) kit and human FGF2 ELISA kit were purchased from BOSTER (Wuhan, China).

Techniques:

a , Schematic summarizing factors and gene markers involved in human cortical area specification. b , Overview of the protocol used to treat neural organoids with patterning factors from 3 to 5 div. Diff, differentiation medium ± vitamin A. c , Percentage of organoids with detectable SP8 > GFP expression after treatment with rostralizing factors (left) or EMX1>mNeonGreen expression after treatment with caudalizing factors (right). CHRDL1, chordin like 1; FST, follistatin; SB, SB-431542 dual SMAD inhibitor; CER1, cerberus 1; CHIR, GSK-3β inhibitor CHIR99021; WNT1, Wnt family member 1. Data indicate the mean ± s.d. from three lines per treatment ( n = 15 organoids per condition and line; except n = 16 for FGF8 high and CHIR low; n = 20, n = 19 and n = 17 for Chir high, and n = 18, n = 19 and n = 17 for Wnt1 treatment for the three lines). P values from one-way analysis of variance (ANOVA; Tukey’s multiple-comparisons test) for comparisons to untreated conditions are provided. d , Experimental procedure for assembloid generation with the SP8 > GFP line and OrEBs. D, day after EB formation; Diff, differentiation medium ± vitamin A; ULA, ultra-low attachment plate . e , RT–qPCR analysis of FGF8 target genes expressed in the SP8 > GFP EBs severed from OrEB after 1 day of co-culture. Data are the log of expression over TBP , shown as the mean ± s.d. ( n = 6 EBs for 0%, n = 5 for 1%, n = 5 for 10% grown from three independent clones). P values are the results of one-way ANOVA. f , GFP intensity of the organoids from g . Whiskers are the minima to maxima, boxes represent the 25th to 75th percentiles (Q1 to Q3) and lines indicate the median ( n = 7 organoids for 0%, n = 11 for 1%, n = 19 for 10%, grown from three independent clones). P values are the results of one-way ANOVA. g , Images of organoids generated with the SP8 > GFP transgenic line and co-culture with OrEBs at 60 div (scale bars, 500 µm). **** P < 0.0001, *** P < 0.001, ** P < 0.01, * P < 0.1. a.u., arbitrary units.

Journal: Nature Methods

Article Title: A polarized FGF8 source specifies frontotemporal signatures in spatially oriented cell populations of cortical assembloids

doi: 10.1038/s41592-024-02412-5

Figure Lengend Snippet: a , Schematic summarizing factors and gene markers involved in human cortical area specification. b , Overview of the protocol used to treat neural organoids with patterning factors from 3 to 5 div. Diff, differentiation medium ± vitamin A. c , Percentage of organoids with detectable SP8 > GFP expression after treatment with rostralizing factors (left) or EMX1>mNeonGreen expression after treatment with caudalizing factors (right). CHRDL1, chordin like 1; FST, follistatin; SB, SB-431542 dual SMAD inhibitor; CER1, cerberus 1; CHIR, GSK-3β inhibitor CHIR99021; WNT1, Wnt family member 1. Data indicate the mean ± s.d. from three lines per treatment ( n = 15 organoids per condition and line; except n = 16 for FGF8 high and CHIR low; n = 20, n = 19 and n = 17 for Chir high, and n = 18, n = 19 and n = 17 for Wnt1 treatment for the three lines). P values from one-way analysis of variance (ANOVA; Tukey’s multiple-comparisons test) for comparisons to untreated conditions are provided. d , Experimental procedure for assembloid generation with the SP8 > GFP line and OrEBs. D, day after EB formation; Diff, differentiation medium ± vitamin A; ULA, ultra-low attachment plate . e , RT–qPCR analysis of FGF8 target genes expressed in the SP8 > GFP EBs severed from OrEB after 1 day of co-culture. Data are the log of expression over TBP , shown as the mean ± s.d. ( n = 6 EBs for 0%, n = 5 for 1%, n = 5 for 10% grown from three independent clones). P values are the results of one-way ANOVA. f , GFP intensity of the organoids from g . Whiskers are the minima to maxima, boxes represent the 25th to 75th percentiles (Q1 to Q3) and lines indicate the median ( n = 7 organoids for 0%, n = 11 for 1%, n = 19 for 10%, grown from three independent clones). P values are the results of one-way ANOVA. g , Images of organoids generated with the SP8 > GFP transgenic line and co-culture with OrEBs at 60 div (scale bars, 500 µm). **** P < 0.0001, *** P < 0.001, ** P < 0.01, * P < 0.1. a.u., arbitrary units.

Article Snippet: Levels of FGF8 protein in cell extracts and supernatants were measured using an ELISA kit (Cusabio CSB-E15861h) according to the manufacturer’s instruction.

Techniques: Expressing, Quantitative RT-PCR, Co-Culture Assay, Clone Assay, Generated, Transgenic Assay

a ) Schematic diagram of CAG > FGF8 reporter (top). Genotyping of the selected clones (bottom) shows the three heterozygotes selected. The PCR was designed to amplify a wild type AAVS1 (WT) amplicon, a left homology arm amplicon (LA), a right homology arm amplicon (RA), and an inner part (IP). b ) RT-qPCR analysis of pluripotency markers and differentiation gene T/BRA in the selected CAG > FGF8 expressing clones and parental wild-type cells. Values are mean ± SD (n = 4 biological replicates for wt; n = 3 biological replicates, one for each CAG > FGF8 clone). P-values resulting from one-way ANOVA (Tukey’s multiple comparisons test) among the different lines are: OCT4 wt vs. OCT4 CAG > FGF8, p = 0.9166; NANOG wt vs. NANOG CAG > FGF8, p = 0.9841; SOX2 wt vs. SOX2 CAG > FGF8, p = 0.9997; TBRA wt vs. TBRA CAG > FGF8, p > 0.9999. c ) Box plots showing RT-qPCR analysis of FGF8 and WNT1 genes in the selected clones of the CAG > FGF8 line compared to wt. Whiskers are min to max, boxes represent the 25th to 75th percentiles (Q1 to Q3); n = 6 from 3 independent clones. One-way ANOVA analysis is p < 0.0001 for FGF8 expression and p > 0.9999 for WNT1 expression. d ) Quantification of FGF8 protein levels in cell lysates (CELLS) and supernatants (SUP) measured by ELISA assay. Values are mean ± SD, n = 6 from 3 independent clones; P-values from two-sided unpaired t-tests are: CELLS wt vs CELLS CAG > FGF8, p = 0.0004; SUP wt vs SUP CAG > FGF8, p = 0.0823.

Journal: Nature Methods

Article Title: A polarized FGF8 source specifies frontotemporal signatures in spatially oriented cell populations of cortical assembloids

doi: 10.1038/s41592-024-02412-5

Figure Lengend Snippet: a ) Schematic diagram of CAG > FGF8 reporter (top). Genotyping of the selected clones (bottom) shows the three heterozygotes selected. The PCR was designed to amplify a wild type AAVS1 (WT) amplicon, a left homology arm amplicon (LA), a right homology arm amplicon (RA), and an inner part (IP). b ) RT-qPCR analysis of pluripotency markers and differentiation gene T/BRA in the selected CAG > FGF8 expressing clones and parental wild-type cells. Values are mean ± SD (n = 4 biological replicates for wt; n = 3 biological replicates, one for each CAG > FGF8 clone). P-values resulting from one-way ANOVA (Tukey’s multiple comparisons test) among the different lines are: OCT4 wt vs. OCT4 CAG > FGF8, p = 0.9166; NANOG wt vs. NANOG CAG > FGF8, p = 0.9841; SOX2 wt vs. SOX2 CAG > FGF8, p = 0.9997; TBRA wt vs. TBRA CAG > FGF8, p > 0.9999. c ) Box plots showing RT-qPCR analysis of FGF8 and WNT1 genes in the selected clones of the CAG > FGF8 line compared to wt. Whiskers are min to max, boxes represent the 25th to 75th percentiles (Q1 to Q3); n = 6 from 3 independent clones. One-way ANOVA analysis is p < 0.0001 for FGF8 expression and p > 0.9999 for WNT1 expression. d ) Quantification of FGF8 protein levels in cell lysates (CELLS) and supernatants (SUP) measured by ELISA assay. Values are mean ± SD, n = 6 from 3 independent clones; P-values from two-sided unpaired t-tests are: CELLS wt vs CELLS CAG > FGF8, p = 0.0004; SUP wt vs SUP CAG > FGF8, p = 0.0823.

Article Snippet: Levels of FGF8 protein in cell extracts and supernatants were measured using an ELISA kit (Cusabio CSB-E15861h) according to the manufacturer’s instruction.

Techniques: Clone Assay, Amplification, Quantitative RT-PCR, Expressing, Enzyme-linked Immunosorbent Assay

a ) Representative images of 4 div embryoid bodies co-cultured with OrEBs containing cells expressing FGF8 and tdTomato mixed at different percentage (0%, 1%, 10%), immunostained for the FGF8 downstream target ETV1 (green) (scale bars 50 µm, the SP8 > GFP organoid is outlined with a dashed contour). The experiment has been repeated 4 times with organoids derived from three independent clones. b ) Immunostaining of 60 div organoids generated with the SP8 > GFP transgenic line and co-cultured with OrEBs in Fig. , stained for the rostral marker LMO4 (scale bars 500 µm in the main panels, 50 µm for the insets). The SP8 > GFP organoid is outlined with a dashed contour. c ) Box plots showing the fraction of LMO4+ cells normalized to total DAPI+ cells in 0%, 1% and 10% FGF8 conditions at 60 div. Whiskers are min to max, boxes represent the 25th to 75th percentiles (Q1 to Q3); n = 8 organoids. P-values from one-way ANOVA (Tukey’s multiple comparisons tests) are: 0% vs 1%, p = 0.0019, 0% vs 10%, p < 0.0001, 1% vs 10%, p < 0.0001. d ) Immunostaining of organoids generated with the SP8 > GFP transgenic line and co-cultured with OrEBs as described in Fig. for 60 days, stained for the neural marker Sox1 and DAPI. Scale bars 500 µm. e ) Quantification of the number of Sox1+ cells over total (DAPI + ) cells. Data show mean ± SD (n = 2 assembloids for 0%, n = 4 assembloids for 1%, n = 3 assembloids for 10%). P-values for each comparison resulting from one-way ANOVA (Tukey’s multiple comparisons tests) are: 0% vs 1%, p = 0.113; 0% vs 10%, p = 0.2171; 1% vs 10%, p = 0.8893. f ) RT-qPCR analysis of anterior ( PAX6, SIX3 ) and optic cup ( SNAI2, PAX3, OTX2, LHX2, RAX ) markers from SP8 > GFP organoids severed from the co-culture experiment at 60 div. Data is Log of expression over TBP, shown as mean ± SD; n = 6 for 0% condition, n = 5 for 1% and 10% condition, from 3 independent clones. P-values from one-way ANOVA (Tukey’s multiple comparisons tests) are: RAX 0% vs. RAX 1%, p = 0.0718; RAX 0% vs. RAX10%, p = 0.0003; RAX 1% vs. RAX 10%, p = 0.0263; all the other comparisons are p < 0.0001. g ) GFP intensity per segment (P, proximal; M, medial; D, distal) in the 1% FGF8 condition from experiments shown in panel b . Each segmented line represents an individual organoid. n = 7 from 3 clones; ns, p = 0.5783 one-way ANOVA. Ns, non-significant. a.u., arbitrary units.

Journal: Nature Methods

Article Title: A polarized FGF8 source specifies frontotemporal signatures in spatially oriented cell populations of cortical assembloids

doi: 10.1038/s41592-024-02412-5

Figure Lengend Snippet: a ) Representative images of 4 div embryoid bodies co-cultured with OrEBs containing cells expressing FGF8 and tdTomato mixed at different percentage (0%, 1%, 10%), immunostained for the FGF8 downstream target ETV1 (green) (scale bars 50 µm, the SP8 > GFP organoid is outlined with a dashed contour). The experiment has been repeated 4 times with organoids derived from three independent clones. b ) Immunostaining of 60 div organoids generated with the SP8 > GFP transgenic line and co-cultured with OrEBs in Fig. , stained for the rostral marker LMO4 (scale bars 500 µm in the main panels, 50 µm for the insets). The SP8 > GFP organoid is outlined with a dashed contour. c ) Box plots showing the fraction of LMO4+ cells normalized to total DAPI+ cells in 0%, 1% and 10% FGF8 conditions at 60 div. Whiskers are min to max, boxes represent the 25th to 75th percentiles (Q1 to Q3); n = 8 organoids. P-values from one-way ANOVA (Tukey’s multiple comparisons tests) are: 0% vs 1%, p = 0.0019, 0% vs 10%, p < 0.0001, 1% vs 10%, p < 0.0001. d ) Immunostaining of organoids generated with the SP8 > GFP transgenic line and co-cultured with OrEBs as described in Fig. for 60 days, stained for the neural marker Sox1 and DAPI. Scale bars 500 µm. e ) Quantification of the number of Sox1+ cells over total (DAPI + ) cells. Data show mean ± SD (n = 2 assembloids for 0%, n = 4 assembloids for 1%, n = 3 assembloids for 10%). P-values for each comparison resulting from one-way ANOVA (Tukey’s multiple comparisons tests) are: 0% vs 1%, p = 0.113; 0% vs 10%, p = 0.2171; 1% vs 10%, p = 0.8893. f ) RT-qPCR analysis of anterior ( PAX6, SIX3 ) and optic cup ( SNAI2, PAX3, OTX2, LHX2, RAX ) markers from SP8 > GFP organoids severed from the co-culture experiment at 60 div. Data is Log of expression over TBP, shown as mean ± SD; n = 6 for 0% condition, n = 5 for 1% and 10% condition, from 3 independent clones. P-values from one-way ANOVA (Tukey’s multiple comparisons tests) are: RAX 0% vs. RAX 1%, p = 0.0718; RAX 0% vs. RAX10%, p = 0.0003; RAX 1% vs. RAX 10%, p = 0.0263; all the other comparisons are p < 0.0001. g ) GFP intensity per segment (P, proximal; M, medial; D, distal) in the 1% FGF8 condition from experiments shown in panel b . Each segmented line represents an individual organoid. n = 7 from 3 clones; ns, p = 0.5783 one-way ANOVA. Ns, non-significant. a.u., arbitrary units.

Article Snippet: Levels of FGF8 protein in cell extracts and supernatants were measured using an ELISA kit (Cusabio CSB-E15861h) according to the manufacturer’s instruction.

Techniques: Cell Culture, Expressing, Derivative Assay, Clone Assay, Immunostaining, Generated, Transgenic Assay, Staining, Marker, Comparison, Quantitative RT-PCR, Co-Culture Assay

a , Experimental procedure for elongated assembloids using mosaic OrEBs containing CAG>tdTOMATO and non-fluorescent CAG > FGF8 -expressing cells. Diff, differentiation medium ± vitamin A. b , Representative images of elongated cortical assembloids at 1 div in the PDMS molds (indicated by white arrows in (i); scale bar, 500 µm), at 7 div after removal from the molds and before Matrigel embedding (ii) or after embedding in large Matrigel droplets ((iii); scale bar, 5 mm), at 120 div in the six-well plate ((iv); scale bar, 5 mm). c , Position of the OrEB on elongated cortical assembloids length (as a percentage) at 15, 60 and 120 div. Values are the mean ± s.d. ( n = 9 organoids for 15 div, n = 11 for 60 div and 120 div grown from three independent clones). P values for comparisons among time points (one-way ANOVA Tukey’s multiple-comparisons test) are: 15 div versus 60 div, P = 0.9455; 15 div versus 120 div, P = 0.9781; 60 div versus 120 div, P > 0.9999. d , Images of elongated cortical assembloids generated with the SP8 > GFP transgenic line and mosaic OrEBs at 60 div (scale bars, 500 µm). Right, SP8 > GFP intensity per segment (P, M and D) in individual assembloids. Each segmented line represents an individual elongated cortical assembloid ( n > 2 from at least 2 clones). P values are the results of one-way ANOVA among segments per condition (0%, P = 0.9045; 1%, P < 0.0001 and 10%, P = 0.9828). e , f , Images of proximal and distal CPNE8 ( e ) or NR2F1 ( f ) stainings (scale bars, 50 µm). Bottom, fraction of CPNE8 + ( e ) or NR2F1 + cells ( f ) normalized to total (DAPI + ) cells in proximal and distal insets of controls (conCAs) and polCAs at 60 div. Whiskers are min to max, boxes represent the 25th to 75th percentiles (Q1 to Q3) and lines indicate the median; CPNE8: n = 20 insets for P and D from 3 conCAs, n = 42 insets for P and n = 39 for D from 3 polCAs; NR2F1: n = 60 insets for P and D from 6 conCAs, n = 40 insets for P and D from 4 polCAs. P values from one-way ANOVA (Tukey’s multiple-comparisons test) are: P = 0.9988 in CPNE8 proximal conCA versus distal conCAs, P = 0.8509 in NR2F1 proximal conCAs versus distal conCAs, P < 0.0001 for other comparisons; NS, not significant. g , g ′, Images of 60 div polCA immunostained with tdTomato in red, DAPI in blue and NR2F1 in white ( g ) or intensity rainbow ( g ′). Scale bar, 500 µm.

Journal: Nature Methods

Article Title: A polarized FGF8 source specifies frontotemporal signatures in spatially oriented cell populations of cortical assembloids

doi: 10.1038/s41592-024-02412-5

Figure Lengend Snippet: a , Experimental procedure for elongated assembloids using mosaic OrEBs containing CAG>tdTOMATO and non-fluorescent CAG > FGF8 -expressing cells. Diff, differentiation medium ± vitamin A. b , Representative images of elongated cortical assembloids at 1 div in the PDMS molds (indicated by white arrows in (i); scale bar, 500 µm), at 7 div after removal from the molds and before Matrigel embedding (ii) or after embedding in large Matrigel droplets ((iii); scale bar, 5 mm), at 120 div in the six-well plate ((iv); scale bar, 5 mm). c , Position of the OrEB on elongated cortical assembloids length (as a percentage) at 15, 60 and 120 div. Values are the mean ± s.d. ( n = 9 organoids for 15 div, n = 11 for 60 div and 120 div grown from three independent clones). P values for comparisons among time points (one-way ANOVA Tukey’s multiple-comparisons test) are: 15 div versus 60 div, P = 0.9455; 15 div versus 120 div, P = 0.9781; 60 div versus 120 div, P > 0.9999. d , Images of elongated cortical assembloids generated with the SP8 > GFP transgenic line and mosaic OrEBs at 60 div (scale bars, 500 µm). Right, SP8 > GFP intensity per segment (P, M and D) in individual assembloids. Each segmented line represents an individual elongated cortical assembloid ( n > 2 from at least 2 clones). P values are the results of one-way ANOVA among segments per condition (0%, P = 0.9045; 1%, P < 0.0001 and 10%, P = 0.9828). e , f , Images of proximal and distal CPNE8 ( e ) or NR2F1 ( f ) stainings (scale bars, 50 µm). Bottom, fraction of CPNE8 + ( e ) or NR2F1 + cells ( f ) normalized to total (DAPI + ) cells in proximal and distal insets of controls (conCAs) and polCAs at 60 div. Whiskers are min to max, boxes represent the 25th to 75th percentiles (Q1 to Q3) and lines indicate the median; CPNE8: n = 20 insets for P and D from 3 conCAs, n = 42 insets for P and n = 39 for D from 3 polCAs; NR2F1: n = 60 insets for P and D from 6 conCAs, n = 40 insets for P and D from 4 polCAs. P values from one-way ANOVA (Tukey’s multiple-comparisons test) are: P = 0.9988 in CPNE8 proximal conCA versus distal conCAs, P = 0.8509 in NR2F1 proximal conCAs versus distal conCAs, P < 0.0001 for other comparisons; NS, not significant. g , g ′, Images of 60 div polCA immunostained with tdTomato in red, DAPI in blue and NR2F1 in white ( g ) or intensity rainbow ( g ′). Scale bar, 500 µm.

Article Snippet: Levels of FGF8 protein in cell extracts and supernatants were measured using an ELISA kit (Cusabio CSB-E15861h) according to the manufacturer’s instruction.

Techniques: Expressing, Clone Assay, Generated, Transgenic Assay

a-b ) Representative images of elongated assembloids (8 div) properly embedded maintaining elongated shape (a) compared to elongated assembloids from the same batch without matrigel, shrinking without spatial constrain (b). c ) Length of elongated assembloids after different days in vitro (div, div1 n = 8, div7 n = 6, div30 n = 4, div60 n = 24, div120 n = 22 assembloids grown from 3 independent clones). P-values resulting from one-way ANOVA Tukey’s multiple comparisons tests) among the different lines are: div1 vs div7, p = 0.0045; div1 vs div30, p = 0.9999; div7 vs div30, p = 0.0366; div7 vs div60, p = 0.9998; div7 vs div120, p = 0.51; div30 vs div60, p = 0.0049; div60 vs div120, p = 0.1825; div1 vs div60, div1 vs div120, div30 vs div120, p < 0.0001. d ) RT-qPCR analysis of neural markers (SOX2, SOX1, SP8 and LMO4), ventral marker NXK2.1 and differentiation markers SNAI1 and T-BRA, in elongated assembloids (eOrg) compared to round organoids (rOrg), after treatment with high FGF8 as described in Fig. . Values are mean ± SD, n = 3 in three lines (hESC H9, H1 and iPSC 178/5). P-values resulting from one-way ANOVA (Tukey’s multiple comparisons tests) are: eORGSOX2 d10 vs. rORGSOX2 d10, p = 0.0024; eORGSOX2 d30 vs. rORGSOX2 d30, p = 0.3144; eORGSOX2 d60 vs. rORGSOX2 d60, p = 0.9434; eORGSOX1 d10 vs. rORGSOX1 d10, p = 0.0009; eORGSOX1 d30 vs. rORGSOX1 d30, p = 0.1573; eORGSOX1 d60 vs. rORGSOX1 d60, p = 0.7266; eORGSP8 d10 vs. rORGSP8 d10, p = 0.0006; eORGSP8 d30 vs. rORGSP8 d30, p = 0.1891; eORGSP8 d60 vs. rORGSP8 d60, p = 0.8004; eORGLMO4 d10 vs. rORGLMO4 d10, p = 0.0114; eORGLMO4 d30 vs. rORGLMO4 d30, p = 0.8378; eORGLMO4 d60 vs. rORGLMO4 d60, p = 0.9821; eORGNKX2.1 d10 vs. rORGNKX2.1 d10, p = 0.0008; eORGNKX2.1 d30 vs. rORGNKX2.1 d30, p = 0.1345; eORGNKX2.1 d60 vs. rORGNKX2.1 d60, p = 0.9036; eORGSNAI1 d10 vs. rORGSNAI1 d10, p = 0.0026; eORGSNAI1 d30 vs. rORGSNAI1 d30, p = 0.6125; eORGSNAI1 d60 vs. rORGSNAI1 d60, p = 0.96; eORGT-BRA d10 vs. rORGT-BRA d10, p = 0.6815; eORGT-BRA d30 vs. rORGT-BRA d30, p = 0.3026; eORGT-BRA d60 vs. rORGT-BRA d60, p = 0.1297. e ) Fraction of TUNEL+ cells normalized to total DAPI+ cells in elongated versus conventional round organoids (div, days in vitro ). N = 36 insets for 4 div elongated, n = 33 for 4 div Round, n = 122 for 7 div elongated, n = 37 for 7 div Round, n = 81 for 30 div elongated, n = 82 for 30 div Round organoids from 3 lines per condition. P-values resulting from one-way ANOVA (Tukey’s multiple comparisons tests) are: 4 div eOrg vs. 4 div rOrg, p < 0.0001; 7 div eOrg vs. 7 div rOrg, p = 0.31; 30 div eOrg vs. 30 div rOrg, p = 0.0115. f ) Box plots showing the fraction of TUNEL+ cells normalized to total DAPI+ cells in proximal and distal insets of elongated assembloids (n = 18 insets for 4 div Proximal and Distal, n = 32 for 7 div Proximal, n = 33 for 7 div Distal, n = 40 for 30 div Proximal, n = 42 for 30 div Distal; organoids are grown from 3 lines per condition). P-values resulting from one-way ANOVA (Tukey’s multiple comparisons tests) are: 4 div proximal vs. 4 div distal, p = 0.6097; 7 div proximal vs. 7 div distal, p = 0.6559; 30 div proximal vs. 30 div distal, p = 0.9897. g ) Representative images of the OrEB localization throughout elongated assembloids growth quantified in Fig. (scale bars 500 µm). h ) Top, representative images of proximal and distal CTIP2 staining (scale bars 50 µm). Bottom, fraction of CTIP2+ cells normalized to total DAPI+ cells in proximal and distal insets of controls (conCA) and polCAs at 60 div (n = 50 insets for P and D conCAs, n = 40 insets for P and D polCAs from 3 organoids). P-values resulting from one-way ANOVA (Tukey’s multiple comparisons tests) are: proximal conCA vs. distal conCA, p = 0.8204; proximal polCA vs. distal polCA, p < 0.0001. i ) Top, representative images of proximal and distal LMO4 staining (scale bars 50 µm). Bottom, fraction of LMO4+ cells normalized to total DAPI+ cells in proximal and distal insets of control(tdt) and polCAs at 60 div (n = 61 insets for P and D from 6 conCAs, n = 51 insets for P and D from 4 polCA). P-values resulting from one-way ANOVA (Tukey’s multiple comparisons tests) are: proximal conCA vs. distal conCA, p > 0.9999; proximal polCA vs. distal polCA, p < 0.0001. ns, non-significant. All whiskers are min to max, boxes represent the 25th to 75th percentiles (Q1 to Q3) and lines indicate median. j-j’ ) Images of immunostained longitudinal sections of elongated assembloids at 60 div (scale bars 500 µm).

Journal: Nature Methods

Article Title: A polarized FGF8 source specifies frontotemporal signatures in spatially oriented cell populations of cortical assembloids

doi: 10.1038/s41592-024-02412-5

Figure Lengend Snippet: a-b ) Representative images of elongated assembloids (8 div) properly embedded maintaining elongated shape (a) compared to elongated assembloids from the same batch without matrigel, shrinking without spatial constrain (b). c ) Length of elongated assembloids after different days in vitro (div, div1 n = 8, div7 n = 6, div30 n = 4, div60 n = 24, div120 n = 22 assembloids grown from 3 independent clones). P-values resulting from one-way ANOVA Tukey’s multiple comparisons tests) among the different lines are: div1 vs div7, p = 0.0045; div1 vs div30, p = 0.9999; div7 vs div30, p = 0.0366; div7 vs div60, p = 0.9998; div7 vs div120, p = 0.51; div30 vs div60, p = 0.0049; div60 vs div120, p = 0.1825; div1 vs div60, div1 vs div120, div30 vs div120, p < 0.0001. d ) RT-qPCR analysis of neural markers (SOX2, SOX1, SP8 and LMO4), ventral marker NXK2.1 and differentiation markers SNAI1 and T-BRA, in elongated assembloids (eOrg) compared to round organoids (rOrg), after treatment with high FGF8 as described in Fig. . Values are mean ± SD, n = 3 in three lines (hESC H9, H1 and iPSC 178/5). P-values resulting from one-way ANOVA (Tukey’s multiple comparisons tests) are: eORGSOX2 d10 vs. rORGSOX2 d10, p = 0.0024; eORGSOX2 d30 vs. rORGSOX2 d30, p = 0.3144; eORGSOX2 d60 vs. rORGSOX2 d60, p = 0.9434; eORGSOX1 d10 vs. rORGSOX1 d10, p = 0.0009; eORGSOX1 d30 vs. rORGSOX1 d30, p = 0.1573; eORGSOX1 d60 vs. rORGSOX1 d60, p = 0.7266; eORGSP8 d10 vs. rORGSP8 d10, p = 0.0006; eORGSP8 d30 vs. rORGSP8 d30, p = 0.1891; eORGSP8 d60 vs. rORGSP8 d60, p = 0.8004; eORGLMO4 d10 vs. rORGLMO4 d10, p = 0.0114; eORGLMO4 d30 vs. rORGLMO4 d30, p = 0.8378; eORGLMO4 d60 vs. rORGLMO4 d60, p = 0.9821; eORGNKX2.1 d10 vs. rORGNKX2.1 d10, p = 0.0008; eORGNKX2.1 d30 vs. rORGNKX2.1 d30, p = 0.1345; eORGNKX2.1 d60 vs. rORGNKX2.1 d60, p = 0.9036; eORGSNAI1 d10 vs. rORGSNAI1 d10, p = 0.0026; eORGSNAI1 d30 vs. rORGSNAI1 d30, p = 0.6125; eORGSNAI1 d60 vs. rORGSNAI1 d60, p = 0.96; eORGT-BRA d10 vs. rORGT-BRA d10, p = 0.6815; eORGT-BRA d30 vs. rORGT-BRA d30, p = 0.3026; eORGT-BRA d60 vs. rORGT-BRA d60, p = 0.1297. e ) Fraction of TUNEL+ cells normalized to total DAPI+ cells in elongated versus conventional round organoids (div, days in vitro ). N = 36 insets for 4 div elongated, n = 33 for 4 div Round, n = 122 for 7 div elongated, n = 37 for 7 div Round, n = 81 for 30 div elongated, n = 82 for 30 div Round organoids from 3 lines per condition. P-values resulting from one-way ANOVA (Tukey’s multiple comparisons tests) are: 4 div eOrg vs. 4 div rOrg, p < 0.0001; 7 div eOrg vs. 7 div rOrg, p = 0.31; 30 div eOrg vs. 30 div rOrg, p = 0.0115. f ) Box plots showing the fraction of TUNEL+ cells normalized to total DAPI+ cells in proximal and distal insets of elongated assembloids (n = 18 insets for 4 div Proximal and Distal, n = 32 for 7 div Proximal, n = 33 for 7 div Distal, n = 40 for 30 div Proximal, n = 42 for 30 div Distal; organoids are grown from 3 lines per condition). P-values resulting from one-way ANOVA (Tukey’s multiple comparisons tests) are: 4 div proximal vs. 4 div distal, p = 0.6097; 7 div proximal vs. 7 div distal, p = 0.6559; 30 div proximal vs. 30 div distal, p = 0.9897. g ) Representative images of the OrEB localization throughout elongated assembloids growth quantified in Fig. (scale bars 500 µm). h ) Top, representative images of proximal and distal CTIP2 staining (scale bars 50 µm). Bottom, fraction of CTIP2+ cells normalized to total DAPI+ cells in proximal and distal insets of controls (conCA) and polCAs at 60 div (n = 50 insets for P and D conCAs, n = 40 insets for P and D polCAs from 3 organoids). P-values resulting from one-way ANOVA (Tukey’s multiple comparisons tests) are: proximal conCA vs. distal conCA, p = 0.8204; proximal polCA vs. distal polCA, p < 0.0001. i ) Top, representative images of proximal and distal LMO4 staining (scale bars 50 µm). Bottom, fraction of LMO4+ cells normalized to total DAPI+ cells in proximal and distal insets of control(tdt) and polCAs at 60 div (n = 61 insets for P and D from 6 conCAs, n = 51 insets for P and D from 4 polCA). P-values resulting from one-way ANOVA (Tukey’s multiple comparisons tests) are: proximal conCA vs. distal conCA, p > 0.9999; proximal polCA vs. distal polCA, p < 0.0001. ns, non-significant. All whiskers are min to max, boxes represent the 25th to 75th percentiles (Q1 to Q3) and lines indicate median. j-j’ ) Images of immunostained longitudinal sections of elongated assembloids at 60 div (scale bars 500 µm).

Article Snippet: Levels of FGF8 protein in cell extracts and supernatants were measured using an ELISA kit (Cusabio CSB-E15861h) according to the manufacturer’s instruction.

Techniques: In Vitro, Clone Assay, Quantitative RT-PCR, Marker, TUNEL Assay, Staining, Control

a ) UMAP embedding for the scRNA-seq dataset containing cells derived from dissections of three segments of polCA and control counterparts annotated by stress levels based on Gruffi analysis. b ) Sankey plot showing similar mapping of cells from individual segments of both control and polCA to stressed cells according to Gruffi’s results. c ) Box plots showing the number of cells expressing FGF8 normalized by the total number of cells per segment for the three replicates. The box displays the median, the inter-quartile range, the minimum and maximum values for each segment. d ) Dot plot for the top five markers for each cluster, genes with logFC> 3 are shown. LogFCs colors are scaled by gene. e ) UMAP embedding plots colored by expression levels of markers of radial glia ( NES, SOX2, VIM ), cycling radial glia ( TOP2A, MKI67 ), Cajal-Retzious cells ( RELN ), neurons ( DCX, TUBB3 ), interneuron progenitor cells ( DLX6-AS1, GAD2 ), LGE-derived progenitors ( GSX2 ), MGE-derived progenitors ( NKX2.1 ), retinal progenitor cells ( RORB, VSX2 ), stress responsive cells ( GOLGA4 ), endothelial cells ( DCN, BGN, COL1A2 ), BMP responsive cells ( TTR, RSPO2, LMX1A, MSX1 ), cilium bearing cells ( PCP4, NPHP1 ), oligodendrocytes ( OLIG1, OLIG2 ), astrocytes ( GFAP, AQP4 ) and microglia ( AIF1, CD68 ).

Journal: Nature Methods

Article Title: A polarized FGF8 source specifies frontotemporal signatures in spatially oriented cell populations of cortical assembloids

doi: 10.1038/s41592-024-02412-5

Figure Lengend Snippet: a ) UMAP embedding for the scRNA-seq dataset containing cells derived from dissections of three segments of polCA and control counterparts annotated by stress levels based on Gruffi analysis. b ) Sankey plot showing similar mapping of cells from individual segments of both control and polCA to stressed cells according to Gruffi’s results. c ) Box plots showing the number of cells expressing FGF8 normalized by the total number of cells per segment for the three replicates. The box displays the median, the inter-quartile range, the minimum and maximum values for each segment. d ) Dot plot for the top five markers for each cluster, genes with logFC> 3 are shown. LogFCs colors are scaled by gene. e ) UMAP embedding plots colored by expression levels of markers of radial glia ( NES, SOX2, VIM ), cycling radial glia ( TOP2A, MKI67 ), Cajal-Retzious cells ( RELN ), neurons ( DCX, TUBB3 ), interneuron progenitor cells ( DLX6-AS1, GAD2 ), LGE-derived progenitors ( GSX2 ), MGE-derived progenitors ( NKX2.1 ), retinal progenitor cells ( RORB, VSX2 ), stress responsive cells ( GOLGA4 ), endothelial cells ( DCN, BGN, COL1A2 ), BMP responsive cells ( TTR, RSPO2, LMX1A, MSX1 ), cilium bearing cells ( PCP4, NPHP1 ), oligodendrocytes ( OLIG1, OLIG2 ), astrocytes ( GFAP, AQP4 ) and microglia ( AIF1, CD68 ).

Article Snippet: Levels of FGF8 protein in cell extracts and supernatants were measured using an ELISA kit (Cusabio CSB-E15861h) according to the manufacturer’s instruction.

Techniques: Derivative Assay, Control, Expressing

Construction, purification, and characterization of FGF21-164. ( A ) FGF21-164 sequence and FGF21 sequence. In the FGF21-164 sequence, red marked the mutated amino acid and blue represents the TR acid sequence from hCD164. In the FGF21 sequence, the red-labeled amino acid represents the amino acid sequence whose n-terminal is deleted in FGF21-164. ( B ) Subcloned cell culture supernatants expressing FGF21-164 and FGF21 were analyzed using Western blotting (Lane M: molecular weight marker. Lane 1~7: FGF21-164 clones 1, 2, 3, A4, B2, F3, and H4. Line 8: FGF21 clone2). ( C ) The purified FGF21-164 and FGF21 were assayed using SDS-PAGE and Western blotting (Lane M: molecular weight marker. Lane 1: purified FGF21-164. Line 2: purified FGF21). ( D ) Purity and hydrodynamic radius of FGF21-164 were analyzed using SEC-HPLC. ( E ) MALDI-TOF mass-spectrometry analysis of FGF21-164. ([M + H] + denotes the singly charged ionic forms, and [M + 2H] 2+ denotes doubly charged ionic forms). ( F ) Circular Dichroism (CD) spectra of FGF21-164 and FGF21.

Journal: International Journal of Molecular Sciences

Article Title: A Novel Recombinant Human FGF21 Analog with High Glycosylation Has a Prolonged Half-Life and Affects Glycemic and Body Weight Control

doi: 10.3390/ijms26062672

Figure Lengend Snippet: Construction, purification, and characterization of FGF21-164. ( A ) FGF21-164 sequence and FGF21 sequence. In the FGF21-164 sequence, red marked the mutated amino acid and blue represents the TR acid sequence from hCD164. In the FGF21 sequence, the red-labeled amino acid represents the amino acid sequence whose n-terminal is deleted in FGF21-164. ( B ) Subcloned cell culture supernatants expressing FGF21-164 and FGF21 were analyzed using Western blotting (Lane M: molecular weight marker. Lane 1~7: FGF21-164 clones 1, 2, 3, A4, B2, F3, and H4. Line 8: FGF21 clone2). ( C ) The purified FGF21-164 and FGF21 were assayed using SDS-PAGE and Western blotting (Lane M: molecular weight marker. Lane 1: purified FGF21-164. Line 2: purified FGF21). ( D ) Purity and hydrodynamic radius of FGF21-164 were analyzed using SEC-HPLC. ( E ) MALDI-TOF mass-spectrometry analysis of FGF21-164. ([M + H] + denotes the singly charged ionic forms, and [M + 2H] 2+ denotes doubly charged ionic forms). ( F ) Circular Dichroism (CD) spectra of FGF21-164 and FGF21.

Article Snippet: Here, we describe a novel human FGF21 analog, designated as FGF21-164, which was generated through fusion protein technology and co-encoded by a mutated FGF21 gene and the TR gene of hCD164.

Techniques: Purification, Sequencing, Labeling, Cell Culture, Expressing, Western Blot, Molecular Weight, Marker, Clone Assay, SDS Page, Mass Spectrometry, Circular Dichroism

Glycan forms analysis of the protein FGF21-164. ( A ) O-linked glycan forms of FGF21-164. ( B ) N-linked glycan forms of FGF21-164.

Journal: International Journal of Molecular Sciences

Article Title: A Novel Recombinant Human FGF21 Analog with High Glycosylation Has a Prolonged Half-Life and Affects Glycemic and Body Weight Control

doi: 10.3390/ijms26062672

Figure Lengend Snippet: Glycan forms analysis of the protein FGF21-164. ( A ) O-linked glycan forms of FGF21-164. ( B ) N-linked glycan forms of FGF21-164.

Article Snippet: Here, we describe a novel human FGF21 analog, designated as FGF21-164, which was generated through fusion protein technology and co-encoded by a mutated FGF21 gene and the TR gene of hCD164.

Techniques:

Effect of FGF21-164 in adipocytes induced by 3T3-L1. ( A ) The process of inducing 3T3-L1’s differentiation into adipocytes. ( B ) Reduction in glucose in medium stimulated by FGF21-164 in adipocytes induced by 3T3-L1. Data are means ± SEM (n = 6). * p < 0.05, *** p < 0.001, and **** p < 0.0001 compared to 0 μg/mL FGF21-164. ( C ) Phospho-Erk1/2-specific bands (Thr202/Tyr204; 44–42 kDa) were detected in 3T3-L1-derived adipocytes after FGF21-164 stimulation. ( D ) Evaluation of lipid droplet accumulation in adipocytes induced by 3T3-L1 with or without FGF21-164. The scale bar represents 50 μm.Data are the means ± SEM (n = 6). * p < 0.05, **** p < 0.0001.

Journal: International Journal of Molecular Sciences

Article Title: A Novel Recombinant Human FGF21 Analog with High Glycosylation Has a Prolonged Half-Life and Affects Glycemic and Body Weight Control

doi: 10.3390/ijms26062672

Figure Lengend Snippet: Effect of FGF21-164 in adipocytes induced by 3T3-L1. ( A ) The process of inducing 3T3-L1’s differentiation into adipocytes. ( B ) Reduction in glucose in medium stimulated by FGF21-164 in adipocytes induced by 3T3-L1. Data are means ± SEM (n = 6). * p < 0.05, *** p < 0.001, and **** p < 0.0001 compared to 0 μg/mL FGF21-164. ( C ) Phospho-Erk1/2-specific bands (Thr202/Tyr204; 44–42 kDa) were detected in 3T3-L1-derived adipocytes after FGF21-164 stimulation. ( D ) Evaluation of lipid droplet accumulation in adipocytes induced by 3T3-L1 with or without FGF21-164. The scale bar represents 50 μm.Data are the means ± SEM (n = 6). * p < 0.05, **** p < 0.0001.

Article Snippet: Here, we describe a novel human FGF21 analog, designated as FGF21-164, which was generated through fusion protein technology and co-encoded by a mutated FGF21 gene and the TR gene of hCD164.

Techniques: Derivative Assay

Pharmacokinetics of FGF21-164. FGF21-164 plasma levels in C57BL/6 mice as determined via targeted LC-MS after i.v. (tail vein) bolus injection of FGF21-164 protein.

Journal: International Journal of Molecular Sciences

Article Title: A Novel Recombinant Human FGF21 Analog with High Glycosylation Has a Prolonged Half-Life and Affects Glycemic and Body Weight Control

doi: 10.3390/ijms26062672

Figure Lengend Snippet: Pharmacokinetics of FGF21-164. FGF21-164 plasma levels in C57BL/6 mice as determined via targeted LC-MS after i.v. (tail vein) bolus injection of FGF21-164 protein.

Article Snippet: Here, we describe a novel human FGF21 analog, designated as FGF21-164, which was generated through fusion protein technology and co-encoded by a mutated FGF21 gene and the TR gene of hCD164.

Techniques: Liquid Chromatography with Mass Spectroscopy, Injection

The results of an oral glucose tolerance test applied to ob / ob mice after a single FGF21-164 treatment. ( A ) Blood glucose levels were measured at 0, 2, 3, 4, 5, 6, 7, and 8 h after the administration of FGF21-164. Data are the means ± SEM (n = 4–5). * p < 0.05 and ** p < 0.01 compared with the model. ( B ) The decrease in blood glucose levels post-administration relative to the baseline measurement at 0 h. Data are the means ± SEM (n = 4–5). * p < 0.05 compared with the model.

Journal: International Journal of Molecular Sciences

Article Title: A Novel Recombinant Human FGF21 Analog with High Glycosylation Has a Prolonged Half-Life and Affects Glycemic and Body Weight Control

doi: 10.3390/ijms26062672

Figure Lengend Snippet: The results of an oral glucose tolerance test applied to ob / ob mice after a single FGF21-164 treatment. ( A ) Blood glucose levels were measured at 0, 2, 3, 4, 5, 6, 7, and 8 h after the administration of FGF21-164. Data are the means ± SEM (n = 4–5). * p < 0.05 and ** p < 0.01 compared with the model. ( B ) The decrease in blood glucose levels post-administration relative to the baseline measurement at 0 h. Data are the means ± SEM (n = 4–5). * p < 0.05 compared with the model.

Article Snippet: Here, we describe a novel human FGF21 analog, designated as FGF21-164, which was generated through fusion protein technology and co-encoded by a mutated FGF21 gene and the TR gene of hCD164.

Techniques:

Effect of a single administration of FGF21-164 on ob / ob mice. ( A , D , G ) Fasting glucose levels. Blood glucose levels were measured at 7, 21, and 28 days after a single dose of FGF21-164 was administered. Data are the means ± SEM (n = 4–5). ns: no significance. * p < 0.05, ** p < 0.01, and **** p < 0.0001. ( B , E , H ) The OGTT at 7, 21, and 28 days. After oral glucose administration, blood glucose levels were measured. Data are the means ± SEM (n = 4–5). * p < 0.05, *** p < 0.001, and **** p < 0.0001 at 6 mg·kg −1 vs. model. # p < 0.05, ## p < 0.01 and #### p < 0.0001 at 12 mg·kg −1 vs. model. ( C , F , I ) The glucose AUC during the OGTT process. Data are the means ± SEM (n = 4–5). ns: no significance. * p < 0.05, *** p < 0.001. ( J ) Body weight measured at 0, 7, 21, and 28 days. Data are the means ± SEM (n = 4–5). ns: no significance.

Journal: International Journal of Molecular Sciences

Article Title: A Novel Recombinant Human FGF21 Analog with High Glycosylation Has a Prolonged Half-Life and Affects Glycemic and Body Weight Control

doi: 10.3390/ijms26062672

Figure Lengend Snippet: Effect of a single administration of FGF21-164 on ob / ob mice. ( A , D , G ) Fasting glucose levels. Blood glucose levels were measured at 7, 21, and 28 days after a single dose of FGF21-164 was administered. Data are the means ± SEM (n = 4–5). ns: no significance. * p < 0.05, ** p < 0.01, and **** p < 0.0001. ( B , E , H ) The OGTT at 7, 21, and 28 days. After oral glucose administration, blood glucose levels were measured. Data are the means ± SEM (n = 4–5). * p < 0.05, *** p < 0.001, and **** p < 0.0001 at 6 mg·kg −1 vs. model. # p < 0.05, ## p < 0.01 and #### p < 0.0001 at 12 mg·kg −1 vs. model. ( C , F , I ) The glucose AUC during the OGTT process. Data are the means ± SEM (n = 4–5). ns: no significance. * p < 0.05, *** p < 0.001. ( J ) Body weight measured at 0, 7, 21, and 28 days. Data are the means ± SEM (n = 4–5). ns: no significance.

Article Snippet: Here, we describe a novel human FGF21 analog, designated as FGF21-164, which was generated through fusion protein technology and co-encoded by a mutated FGF21 gene and the TR gene of hCD164.

Techniques:

Effect of repeated administration of FGF21-164. ( A ) Body weight changes. The DIO mice were treated with PBS or FGF21-164 once every 2 days. Data are the means ± SEM (n = 5–7). **** p < 0.0001 vs. Ctrl. #### p < 0.0001 for FGF21-164 vs. the model. ( B ) The liver sections were stained with Oil-red-O. The scale bar represents 100 μm. DIO mice showed many red lipid droplets in hepatic tissue (indicated by the black arrow), while lipid droplet levels were lower after the FGF21-164 treatment.

Journal: International Journal of Molecular Sciences

Article Title: A Novel Recombinant Human FGF21 Analog with High Glycosylation Has a Prolonged Half-Life and Affects Glycemic and Body Weight Control

doi: 10.3390/ijms26062672

Figure Lengend Snippet: Effect of repeated administration of FGF21-164. ( A ) Body weight changes. The DIO mice were treated with PBS or FGF21-164 once every 2 days. Data are the means ± SEM (n = 5–7). **** p < 0.0001 vs. Ctrl. #### p < 0.0001 for FGF21-164 vs. the model. ( B ) The liver sections were stained with Oil-red-O. The scale bar represents 100 μm. DIO mice showed many red lipid droplets in hepatic tissue (indicated by the black arrow), while lipid droplet levels were lower after the FGF21-164 treatment.

Article Snippet: Here, we describe a novel human FGF21 analog, designated as FGF21-164, which was generated through fusion protein technology and co-encoded by a mutated FGF21 gene and the TR gene of hCD164.

Techniques: Staining

IHC staining of mp53 in SCCHN samples shows mainly nuclear and some cytoplasmic expression patterns. IHC staining of FGFR3 shows membrane and cytoplasmic expression. Four representative images are presented: mp53+/FGFR3+, mp53+/FGFR3-, mp53-/FGFR3+, mp53-/FGFR3- and negative control. (200 x magnification).

Journal: PLoS ONE

Article Title: Co-expression of fibroblast growth factor receptor 3 with mutant p53, and its association with worse outcome in oropharyngeal squamous cell carcinoma

doi: 10.1371/journal.pone.0247498

Figure Lengend Snippet: IHC staining of mp53 in SCCHN samples shows mainly nuclear and some cytoplasmic expression patterns. IHC staining of FGFR3 shows membrane and cytoplasmic expression. Four representative images are presented: mp53+/FGFR3+, mp53+/FGFR3-, mp53-/FGFR3+, mp53-/FGFR3- and negative control. (200 x magnification).

Article Snippet: Besides hematoxylin and eosin (H&E) staining, standard immunohistochemistry (IHC) was used to stain for p16 (1:100, Delta Biolab, Gilroy, CA), FGFR3 (PA2143, Boster Bio, Pleasanton, CA.) and mp53 (AB32049, Abcam, Cambridge, MA.) using primary antibodies followed by corresponding secondary antibodies, visualized by DAB and counterstained with hematoxylin.

Techniques: Immunohistochemistry, Expressing, Membrane, Negative Control

Univariate association of  FGFR3  with clinical characteristics in cohort 1.

Journal: PLoS ONE

Article Title: Co-expression of fibroblast growth factor receptor 3 with mutant p53, and its association with worse outcome in oropharyngeal squamous cell carcinoma

doi: 10.1371/journal.pone.0247498

Figure Lengend Snippet: Univariate association of FGFR3 with clinical characteristics in cohort 1.

Article Snippet: Besides hematoxylin and eosin (H&E) staining, standard immunohistochemistry (IHC) was used to stain for p16 (1:100, Delta Biolab, Gilroy, CA), FGFR3 (PA2143, Boster Bio, Pleasanton, CA.) and mp53 (AB32049, Abcam, Cambridge, MA.) using primary antibodies followed by corresponding secondary antibodies, visualized by DAB and counterstained with hematoxylin.

Techniques:

 FGFR3  association with clinical characteristics in cohort 2.

Journal: PLoS ONE

Article Title: Co-expression of fibroblast growth factor receptor 3 with mutant p53, and its association with worse outcome in oropharyngeal squamous cell carcinoma

doi: 10.1371/journal.pone.0247498

Figure Lengend Snippet: FGFR3 association with clinical characteristics in cohort 2.

Article Snippet: Besides hematoxylin and eosin (H&E) staining, standard immunohistochemistry (IHC) was used to stain for p16 (1:100, Delta Biolab, Gilroy, CA), FGFR3 (PA2143, Boster Bio, Pleasanton, CA.) and mp53 (AB32049, Abcam, Cambridge, MA.) using primary antibodies followed by corresponding secondary antibodies, visualized by DAB and counterstained with hematoxylin.

Techniques:

Correlation of  FGFR3  with p53 and mp53 in cohort 1.

Journal: PLoS ONE

Article Title: Co-expression of fibroblast growth factor receptor 3 with mutant p53, and its association with worse outcome in oropharyngeal squamous cell carcinoma

doi: 10.1371/journal.pone.0247498

Figure Lengend Snippet: Correlation of FGFR3 with p53 and mp53 in cohort 1.

Article Snippet: Besides hematoxylin and eosin (H&E) staining, standard immunohistochemistry (IHC) was used to stain for p16 (1:100, Delta Biolab, Gilroy, CA), FGFR3 (PA2143, Boster Bio, Pleasanton, CA.) and mp53 (AB32049, Abcam, Cambridge, MA.) using primary antibodies followed by corresponding secondary antibodies, visualized by DAB and counterstained with hematoxylin.

Techniques:

Pearson correlation coefficients (p-values) between  FGFR3  and mp53, cytoplasmic and nuclear mp53 when p16 is negative.

Journal: PLoS ONE

Article Title: Co-expression of fibroblast growth factor receptor 3 with mutant p53, and its association with worse outcome in oropharyngeal squamous cell carcinoma

doi: 10.1371/journal.pone.0247498

Figure Lengend Snippet: Pearson correlation coefficients (p-values) between FGFR3 and mp53, cytoplasmic and nuclear mp53 when p16 is negative.

Article Snippet: Besides hematoxylin and eosin (H&E) staining, standard immunohistochemistry (IHC) was used to stain for p16 (1:100, Delta Biolab, Gilroy, CA), FGFR3 (PA2143, Boster Bio, Pleasanton, CA.) and mp53 (AB32049, Abcam, Cambridge, MA.) using primary antibodies followed by corresponding secondary antibodies, visualized by DAB and counterstained with hematoxylin.

Techniques:

Pearson correlation coefficients (p-values) between  FGFR3  and mp53, cytoplasmic and nuclear mp53 when p16 is positive.

Journal: PLoS ONE

Article Title: Co-expression of fibroblast growth factor receptor 3 with mutant p53, and its association with worse outcome in oropharyngeal squamous cell carcinoma

doi: 10.1371/journal.pone.0247498

Figure Lengend Snippet: Pearson correlation coefficients (p-values) between FGFR3 and mp53, cytoplasmic and nuclear mp53 when p16 is positive.

Article Snippet: Besides hematoxylin and eosin (H&E) staining, standard immunohistochemistry (IHC) was used to stain for p16 (1:100, Delta Biolab, Gilroy, CA), FGFR3 (PA2143, Boster Bio, Pleasanton, CA.) and mp53 (AB32049, Abcam, Cambridge, MA.) using primary antibodies followed by corresponding secondary antibodies, visualized by DAB and counterstained with hematoxylin.

Techniques:

Cohort 1, univariate analysis of overall survival.

Journal: PLoS ONE

Article Title: Co-expression of fibroblast growth factor receptor 3 with mutant p53, and its association with worse outcome in oropharyngeal squamous cell carcinoma

doi: 10.1371/journal.pone.0247498

Figure Lengend Snippet: Cohort 1, univariate analysis of overall survival.

Article Snippet: Besides hematoxylin and eosin (H&E) staining, standard immunohistochemistry (IHC) was used to stain for p16 (1:100, Delta Biolab, Gilroy, CA), FGFR3 (PA2143, Boster Bio, Pleasanton, CA.) and mp53 (AB32049, Abcam, Cambridge, MA.) using primary antibodies followed by corresponding secondary antibodies, visualized by DAB and counterstained with hematoxylin.

Techniques:

Cohort 1, univariate analysis of disease free survival.

Journal: PLoS ONE

Article Title: Co-expression of fibroblast growth factor receptor 3 with mutant p53, and its association with worse outcome in oropharyngeal squamous cell carcinoma

doi: 10.1371/journal.pone.0247498

Figure Lengend Snippet: Cohort 1, univariate analysis of disease free survival.

Article Snippet: Besides hematoxylin and eosin (H&E) staining, standard immunohistochemistry (IHC) was used to stain for p16 (1:100, Delta Biolab, Gilroy, CA), FGFR3 (PA2143, Boster Bio, Pleasanton, CA.) and mp53 (AB32049, Abcam, Cambridge, MA.) using primary antibodies followed by corresponding secondary antibodies, visualized by DAB and counterstained with hematoxylin.

Techniques:

Multivariate survival analysis on disease free survival.

Journal: PLoS ONE

Article Title: Co-expression of fibroblast growth factor receptor 3 with mutant p53, and its association with worse outcome in oropharyngeal squamous cell carcinoma

doi: 10.1371/journal.pone.0247498

Figure Lengend Snippet: Multivariate survival analysis on disease free survival.

Article Snippet: Besides hematoxylin and eosin (H&E) staining, standard immunohistochemistry (IHC) was used to stain for p16 (1:100, Delta Biolab, Gilroy, CA), FGFR3 (PA2143, Boster Bio, Pleasanton, CA.) and mp53 (AB32049, Abcam, Cambridge, MA.) using primary antibodies followed by corresponding secondary antibodies, visualized by DAB and counterstained with hematoxylin.

Techniques:

KM plots were generated using median weighted index (WI) of mp53 (3.5) and FGFR3 (35) as the cut off values (>median as positive and ≤ median as negative). High FGFR3 and mp53 levels correlated with worse OS (A) and DFS (B).

Journal: PLoS ONE

Article Title: Co-expression of fibroblast growth factor receptor 3 with mutant p53, and its association with worse outcome in oropharyngeal squamous cell carcinoma

doi: 10.1371/journal.pone.0247498

Figure Lengend Snippet: KM plots were generated using median weighted index (WI) of mp53 (3.5) and FGFR3 (35) as the cut off values (>median as positive and ≤ median as negative). High FGFR3 and mp53 levels correlated with worse OS (A) and DFS (B).

Article Snippet: Besides hematoxylin and eosin (H&E) staining, standard immunohistochemistry (IHC) was used to stain for p16 (1:100, Delta Biolab, Gilroy, CA), FGFR3 (PA2143, Boster Bio, Pleasanton, CA.) and mp53 (AB32049, Abcam, Cambridge, MA.) using primary antibodies followed by corresponding secondary antibodies, visualized by DAB and counterstained with hematoxylin.

Techniques: Generated